Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics to Share Innovative Lenalidomide Delivery Technology on Labroots Webinar Sponsored by Primetech Corporation

PARAMUS, N.J., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
October 02, 2025 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics Announces Promotion of Rod Hartwig to Vice President of Research and Development and Manufacturing

PARAMUS, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
October 01, 2025 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025

PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
September 16, 2025 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD

New U.S. patent provides IP coverage for the formulation to 2042Further expands Starton’s intellectual property portfolio surrounding its lead product candidate, STAR-LLD, Method of Use Patent...
June 24, 2025 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)

PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous...
June 12, 2025 16:01 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigatorSecond site, Regional Medical Oncology Center, also activatedRecent Phase 1b...
April 25, 2025 13:10 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal...
March 26, 2025 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., March 26, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
December 03, 2024 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics to Present at Biotech Showcase 2025

PARAMUS, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with...
October 29, 2024 08:00 ET | Source: Starton Therapeutics Inc.

Starton Therapeutics Announces Notice of Allowance for U.S. Patent Application 17/518,930 “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” Including Transdermal Administration

Significantly expands scope of patent coverage for Company’s proprietary drug delivery systems to now include transdermal deliveryPatent expected to issue from the pending application will have term...